Imoto S, Aoki M, Shimpo K, Yamashita K
J Toxicol Sci. 1987 Feb;12 Suppl 1:1-33. doi: 10.2131/jts.12.supplementi_1.
A chronic oral toxicity test of proglumetacin maleate (PGM), an anti-inflammatory agent, was studied at dose-levels of 0, 0.6, 2.5 and 10.0 mg/kg/day using male and female beagle dogs. They were treated for 12 months, followed by 1 month recovery period. Excretion soft and mucous feces was observed in females of 2.5 mg/kg/day group. In addition, excretion of diarrheal and blood-tinged feces was also found in females of 10.0 mg/kg/day group. One female animal given 10.0 mg/kg/day of PGM was found dead on day 178 of administration. For about a month before death, diarrheal and blood-tinged feces, decreases in body weight and food consumption, and anemia had been noticed. At the autopsy, brown-cloudy ascitic fluid, adhesion of visceral organs, hyperemia or hemorrhage in the mucosa and serosa of the digestive tract, and an ulcer in the duodenum were found. No significant influences of PGM were noted on the changes of body weights, food and water consumptions, excluding the dead animal. A fecal occult blood test showed an increase in no. of animals with blood-positive reaction in 2.5 and 10.0 mg/kg/day groups of both sexes, especially marked in females of 10.0 mg/kg/day group. In urinary tests, no significant changes were found in any of the PGM-treated groups of both sexes; the dead one, however, showed decreases in urine volume and electrolyte excretion on month 6 of administration. No significant hematological changes associated with the administration of PGM were found in any of the animals excluding the dead one, in which anemia and inflammation-related findings were found on month 6 of administration. Serum-biochemical tests showed no significant changes in any of the PGM-treated groups of both sexes. No significant influences of PGM were found on ICG and PSP clearances, ocular fundus and ECG. At the autopsy performed at the end of administration, no significant changes were found in any of the PGM-treated groups of both sexes. Histopathologically, a duodenal ulcer and peritonitis-related findings were observed in the female dead animal of 10.0 mg/kg/day group. No influences of PGM were found in any of the tests performed at the end of the recovery phase. From these results, the non-effective dose of PGM was estimated to be 0.6 mg/kg/day, and the toxic doses of PGM to be more than 10.0 mg/kg/day for males and 10.0 mg/kg/day for females, respectively, in beagle dogs treated orally with PGM for 12 months.
使用雄性和雌性比格犬,在0、0.6、2.5和10.0毫克/千克/天的剂量水平下,对比格美辛马来酸盐(PGM,一种抗炎剂)进行了慢性经口毒性试验。它们接受了12个月的治疗,随后有1个月的恢复期。在2.5毫克/千克/天组的雌性犬中观察到软便和黏液便排泄。此外,在10.0毫克/千克/天组的雌性犬中还发现了腹泻便和带血粪便的排泄。一只给予10.0毫克/千克/天PGM的雌性动物在给药第178天死亡。在死亡前约一个月,观察到腹泻便和带血粪便、体重和食物摄入量下降以及贫血。尸检时,发现有棕色浑浊腹水、内脏器官粘连、消化道黏膜和浆膜充血或出血以及十二指肠溃疡。除死亡动物外,PGM对体重、食物和水摄入量的变化未产生显著影响。粪便潜血试验显示,在2.5和10.0毫克/千克/天的两性组中,呈血阳性反应的动物数量增加,在10.0毫克/千克/天组的雌性动物中尤为明显。在尿液检测中,PGM处理的两性组均未发现显著变化;然而,死亡动物在给药第6个月时尿量和电解质排泄减少。除死亡动物外,在任何动物中均未发现与PGM给药相关的显著血液学变化,死亡动物在给药第6个月时出现贫血和炎症相关表现。血清生化检测显示,PGM处理的两性组均未发现显著变化。PGM对吲哚氰绿(ICG)和酚红(PSP)清除率、眼底和心电图均无显著影响。在给药结束时进行的尸检中,PGM处理的两性组均未发现显著变化。组织病理学检查发现,10.0毫克/千克/天组的雌性死亡动物有十二指肠溃疡和腹膜炎相关表现。在恢复期结束时进行的任何检测中均未发现PGM有影响。根据这些结果,在经口给予PGM 12个月的比格犬中,PGM的无作用剂量估计为0.6毫克/千克/天,PGM对雄性的毒性剂量分别大于10.0毫克/千克/天,对雌性的毒性剂量大于10.0毫克/千克/天。